<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002228</url>
  </required_header>
  <id_info>
    <org_study_id>295A</org_study_id>
    <secondary_id>TRI-003</secondary_id>
    <nct_id>NCT00002228</nct_id>
  </id_info>
  <brief_title>A Study of T-20 in HIV-Positive Adults</brief_title>
  <official_title>A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trimeris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive&#xD;
      adults. T-20 is an anti-HIV drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by&#xD;
      subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks;&#xD;
      including a 2-week screening period, followed by 28 days of treatment and 1 week of&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>78</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enfuvirtide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the&#xD;
             screening visit.&#xD;
&#xD;
          -  Antibiotics for bacterial infections.&#xD;
&#xD;
          -  Prophylactic medications for P. carinii pneumonia and for M. avium, including&#xD;
             azithromycin.&#xD;
&#xD;
          -  Medications for symptomatic treatment such as antipyretics, analgesics, and&#xD;
             antiemetics.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
        HIV-1 seropositive status.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
        Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the&#xD;
        cervix, and non-disseminated stable Kaposi's sarcoma).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Patients must not be taking any concurrent antiretroviral therapy (for at least 2&#xD;
             weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen&#xD;
             which has not changed for at least 6 weeks prior to baseline.&#xD;
&#xD;
          -  Treatment with any of the following:&#xD;
&#xD;
          -  immunomodulators, biological response modifiers, chemotherapy that cannot be&#xD;
             discontinued for the duration of the study, astemizole, terfenadine, cisapride,&#xD;
             triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30&#xD;
             days prior to the initial visit.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Evidence of active opportunistic infections, or unexplained temperature greater than&#xD;
             or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening&#xD;
             visit.&#xD;
&#xD;
          -  Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for&#xD;
             15 days) within 30 days prior to screening visit.&#xD;
&#xD;
          -  Diagnosis of hemophilia or other clotting disorders.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Prior treatment with an HIV vaccine.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Major organ allograft.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Evidence of substance abuse or addiction that, in the opinion of the investigator, may&#xD;
        interfere with the patient's ability to comply with the dosing schedule and protocol&#xD;
        evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Hopkins</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham / 1917 AIDS O/P Cln</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine / Ctr for Research and Education</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900951793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDC Research Initiative</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ / Infect Dis Div / Pasavant Pav 828</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI of New England</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med Ctr / C &amp; D Building</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ North Carolina at Chapel Hill / Dept of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas / Thomas Street Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Injections, Subcutaneous</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>peptide T20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

